OncoMatch/Clinical Trials/NCT06643884
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Official title: A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid
Is NCT06643884 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including AU-011 and SCS Microinjector for eye cancer.
Treatment: AU-011 · SCS Microinjector · Laser — The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Check if I qualifyEligibility summary
For patients with Metastatic Cancer to the Choroid. Requires metastatic disease.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- Byers Eye Institute at Stanford University · Palo Alto, California
- Bascom Palmer Eye Institute · Miami, Florida
- Massachusetts Eye and Ear · Boston, Massachusetts
- Kellogg Eye Center · Ann Arbor, Michigan
- Associated Retinal Consultants (ARC) PC · Royal Oak, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06643884 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify